News | March 10, 2009

ValveXchange's Heart Valve Technology Wins Frost & Sullivan Award

March 10, 2009 - Frost & Sullivan bestowed its 2009 North American Technology Innovation of the Year Award on ValveXchange Inc. for developing the innovative ValveXchange Heart Valve System.

Based on a two-part bioprosthetic tissue valve, the patented system promises to mitigate the compromises between traditional mechanical and tissue heart valves while providing maximal patient benefits.

The ValveXchange system comprises a two-part valve and associated tools to facilitate initial implantation and subsequent leaflet-set exchange. The docking station, a permanent fixture, is surgically implanted and provides the basic support for the replaceable leaflet set. In other bioprosthetic valves, particularly bovine pericardial valves, the pericardial tissue leaflets are permanently attached to the support frame. In the ValveXchange valve, three clips are employed for holding the leaflet set in place. When the leaflet set needs a replacement, typically many years after its initial implantation, a specific-exchange tool releases it, reportedly in a foolproof manner. The exchange tool then is loaded with a new leaflet set that quickly snaps onto the docking station providing new-valve performance.

"The ValveXchange Heart Valve System represents a safe and less invasive alternative to conventional therapies as a docking station for the prosthetic valve is installed during the initial surgery itself," said Frost & Sullivan Research Analyst S.R. Priya. "Later, when a replacement of the worn out valve leaflet set is needed, the replacement leaflet is conveniently substituted without the need for a full open-heart surgical valve replacement.

"ValveXchange is designing the system for a wide variety of surgical options for the leaflet exchange, including through a very small incision using a minimally invasive procedure, which does not necessitate cardiopulmonary bypass," added Priya. "As research and development continues in the future, varied patterns and materials of the leaflet set can be incorporated into the exchangeable component."

The performance of the ValveXchange valve is designed to be on par with the Edwards bovine pericardial valve, the most commonly used tissue valve. Furthermore, the ValveXchange technology adapts to the aortic valve position, the first planned product, and later to the mitral and other valve positions. The docking station can be sewn into location without the valve leaflets in place allowing for maximum ease and flexibility for surgical implant. In the future, this can also allow the possibility of staples or mechanized suturing to be employed.

"Overall, the ValveXchange system provides the innate hemodynamic and non-thrombogenic benefits of tissue valves to patients of all ages, thus obviating the need for expensive and potentially problematic anti-coagulation therapies and major lifestyle modifications," concluded Priya.

ValveXchange Inc. products have not been approved by the U.S. FDA.

For more information: www.frost.com, www.valvexchange.com

Related Content

Appropriate Use Criteria Published for Valvular Heart Disease Imaging Tests
News | Clinical Decision Support| October 16, 2017
The American College of Cardiology (ACC), along with several partnering societies, recently released appropriate use...
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Overlay Init